hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:医生快帮我!下面有虫子!?!?”
下一页:癫痫患者手术评估新型工具
- 2022-04-25造成高血压经常发作的病因是什么
- 2022-04-25癫痫孕妇使用抗癫痫药物就会增加流产风险吗?
- 2022-04-12预测癫痫患者再入院风险
- 2022-04-11IBD: 炎性肠病患者门静脉血栓形成的发生风险分析
- 2022-04-06癫痫猝死:凶手是谁?
- 2022-04-05抗癫痫药物预防新发癫痫:任重而道远
- FDA批准Aptiom用于治疗患者癫痫发作
- 预测癫痫患者再入院风险
- IBD: 炎性肠病患者门静脉血栓形成的发生风险分析
- 癫痫猝死:凶手是谁?
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫治疗障碍仍难以克服
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 月经性癫痫患者妊娠期癫痫控制更好
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 黑芝麻的营养价值 吃黑芝麻的好处
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 凌腾医学宣布,卡妥索双抗对介苗治疗失败的非肌层浸润性膀胱癌的第一次临床试验已经完成
- 特发性癫痫大发作药物治疗的首选
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 控制癫痫患者再次抽搐,不包括可选药物?
- 羊角病能生孩子吗?
- 癫痫会遗传吗 癫痫的治疗方法
- 综述:癫痫持续状态诊治最新进展
- 自身免疫病也可以免疫治疗
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 子宫腺肌病不治疗的后果是什么?
- 癫痫患者手术评估新型工具
- 2013国际抗癫痫联合会抗癫痫药用指南
- 医生快帮我!下面有虫子!?!?”
- 癫痫病小发作腹泻 这些腹泻就是癫痫小发作
- 失眠只是呆不好而已吗?
- 专家告诉你癫痫病的化疗好方法
- 罗氏制药发布致医生信警示甲氟喹的神经精神痉挛
- 癫痫病的成因有哪些怎么治好
- 治好癫痫病的新方法哪个好
- FDA对怀孕期间用于丙戊酸钠类药物发出警告
- 加剧癫痫病的病因都有什么
- 癫痫病症状 怎样护理人员癫痫病人
- 记好癫痫日记,让住院治疗事半功倍
- 《柳叶刀》力挺:中国饮食有3大健康杀手,血管病和癌症世界第一
- 2015年第31届国际病症大会(IEC)
- 去广州儿童医院|小儿癫痫的病征有哪些?
- 癫痫的治疗 治疗癫痫的;也大全